Russia's Sputnik V vaccine developers question neutrality of EU regulator, want apology

MOSCOW (Reuters) – The developers of Russia’s Sputnik V vaccine against COVID-19 on Tuesday questioned the neutrality of the European Medicines Agency (EMA) after an EMA official urged EU members to refrain from approving the Russian vaccine for now.

FILE PHOTO: A medical worker holds a syringe with Sputnik V vaccine against the coronavirus disease (COVID-19) at a vaccination centre in Saint Petersburg, Russia February 24, 2021. REUTERS/Anton Vaganov

Christa Wirthumer-Hoche, the head of EMA’s management board, told a talk show on Austrian broadcaster ORF on March 7 that she advised European Union countries against granting Sputnik V a national emergency authorisation while EMA was still reviewing the Russian vaccine’s safety and effectiveness.

“We demand a public apology from EMA’s Christa Wirthumer-Hoche for her negative comments on EU states directly approving Sputnik V,” the vaccine developers wrote on the official Sputnik V Twitter account.

“Her comments raise serious questions about possible political interference in the ongoing EMA review,” they said.

The developers added that the vaccine had already been approved by 46 countries.

“After postponing Sputnik V review for months, EMA does not have the right to undermine (the) credibility of 46 other regulators that reviewed all of the necessary data,” Sputnik V’s developers said.

Sputnik V has already been approved or is being assessed for approval in three EU member states – Hungary, Slovakia and the Czech Republic. EU officials have said Brussels could start negotiations with a vaccine maker if at least four member countries request it.

Kirill Dmitriev, head of Russia’s RDIF sovereign wealth fund, which markets Sputnik V abroad, told Italian television on Sunday it was collaborating with pharmaceutical company Adienne to produce the vaccine in Italy.

The Italian-Russian Chamber of Commerce later said there were plans for production to start in Italy in June and that the deal paved the way to create the first Sputnik V production facility in Europe.

EMA earlier this month said it would review data from ongoing trials of the vaccine until there was enough evidence for a formal marketing authorisation application.

Source: Read Full Article